Novo A/S
13F Reported Value
ⓘ$1.2B
Holdings
22
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Novo A/S disclosed 22 positions worth $1.2B in its Form 13F-HR for Q1 2026, led by $EWTX (Edgewise Therapeutics, Inc.) at 13.7% of the equity portfolio, followed by $BN and $ASML. During the quarter the fund opened 1 new position and exited 3 — including a new stake in $XENE and a full exit from $ZBIO. The portfolio is most concentrated in Healthcare (69.5% of disclosed assets). All figures are sourced directly from Novo A/S’s Form 13F-HR filing with the SEC under CIK 1388325.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$168.5M5,350,000 sh - —
Quality
$141.5M3,496,245 sh - —
Quality
$125.4M94,946 sh - 32.7
Quality
$122.4M1,325,000 sh - —
Quality
$74.9M3,686,622 sh - 75.2
Quality
$73.4M393,187 sh - 26.5
Quality
$56.3M1,550,000 sh - —
Quality
$50.2M1,280,000 sh - —
Quality
$50.0M860,000 sh - —
Quality
$49.4M1,750,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Edgewise Therapeutics, Inc.$EWTX | — | $168.5M | 5,350,000 |
 BROOKFIELD Corp /ON/$BN | — | $141.5M | 3,496,245 |
 ASML HOLDING NV$ASML | — | $125.4M | 94,946 |
 Mirum Pharmaceuticals, Inc.$MIRM | 32.7 | $122.4M | 1,325,000 |
 MapLight Therapeutics, Inc.$MPLT | — | $74.9M | 3,686,622 |
 Salesforce, Inc.$CRM | 75.2 | $73.4M | 393,187 |
 Crinetics Pharmaceuticals, Inc.$CRNX | 26.5 | $56.3M | 1,550,000 |
 Enliven Therapeutics, Inc.$ELVN | — | $50.2M | 1,280,000 |
 Vaxcyte, Inc.$PCVX | — | $50.0M | 860,000 |
 Pharvaris N.V.$PHVS | — | $49.4M | 1,750,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Novo A/S's 22 positions.
Showing top 10 of 22 holdings.
Sector Allocation
Healthcare
$857.3M
Industrials
$157.7M
Real Estate
$141.5M
Technology
$75.2M
Materials
$2.5M
Full Holdings — Novo A/S (Q1 2026)
All 22 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $EWTX | Edgewise Therapeutics, Inc. | $168.5M | 13.7% | +0% | — |
| 2 | $BN | BROOKFIELD Corp /ON/ | $141.5M | 11.5% | +0% | — |
| 3 | $ASML | ASML HOLDING NV | $125.4M | 10.2% | -17% | — |
| 4 | $MIRM | Mirum Pharmaceuticals, Inc. | $122.4M | 9.9% | +5% | 32.7 |
| 5 | $MPLT | MapLight Therapeutics, Inc. | $74.9M | 6.1% | +0% | — |
| 6 | $CRM | Salesforce, Inc. | $73.4M | 6.0% | +19% | 75.2 |
| 7 | $CRNX | Crinetics Pharmaceuticals, Inc. | $56.3M | 4.6% | -5% | 26.5 |
| 8 | $ELVN | Enliven Therapeutics, Inc. | $50.2M | 4.1% | -14% | — |
| 9 | $PCVX | Vaxcyte, Inc. | $50.0M | 4.0% | -6% | — |
| 10 | $PHVS | Pharvaris N.V. | $49.4M | 4.0% | +0% | — |
| 11 |  $AVBP | ArriVent BioPharma, Inc. | $44.8M | 3.6% | +0% | — |
| 12 |  $VRDN | Viridian Therapeutics, Inc.\DE | $39.1M | 3.2% | -16% | 30.5 |
| 13 |  $CLDX | Celldex Therapeutics, Inc. | $38.1M | 3.1% | +0% | 13.2 |
| 14 |  $APGE | Apogee Therapeutics, Inc. | $37.9M | 3.1% | -21% | — |
| 15 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $37.3M | 3.0% | +0% | 74.1 |
| 16 |  $FDMT | 4D Molecular Therapeutics, Inc. | $34.0M | 2.8% | +0% | 23.2 |
| 17 |  $BABA | Alibaba Group Holding Ltd | $32.3M | 2.6% | +0% | — |
| 18 |  $XENE | Xenon Pharmaceuticals Inc. | $28.2M | 2.3% | NEW | 12.9 |
| 19 |  $BBOT | BridgeBio Oncology Therapeutics, Inc. | $19.6M | 1.6% | +11% | — |
| 20 |  $VALN | Valneva SE | $6.6M | 0.5% | -54% | 33.3 |
| 21 |  $LNZA | LanzaTech Global, Inc. | $2.5M | 0.2% | +0% | 8 |
| 22 |  $MQ | Marqeta, Inc. | $1.8M | 0.1% | +0% | 40.2 |
New Positions (1)
$XENE Xenon Pharmaceuticals Inc.$28.2M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Novo A/S including:
Track Novo A/S's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Novo A/S and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Novo A/S
13F Pro is an AI hedge fund tracker and stock research platform. For Novo A/S (SEC CIK: 1388325), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Novo A/S's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.